- News
News
Welcome to the homepage of AIHTA!
AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: The Entrepreneurial State: Ode an die öffentliche Hand
- EXOGEN™ für die die Behandlung nicht heilender Knochenbrüche
- CRP (C-reaktives Protein): Messung bei akuten Infektionen der Atemwege in der Primärversorgung
- Gesundheitliche Versorgung von vulnerablen Personen – Methoden der Evaluation
- E-Zigarette: Probates Mittel zur Raucherentwöhnung?
- Termine
- Themen-Vorschau
Announcement
Evaluation methods for the benefit assessment of easily accessible, out-patient health centers for vulnerable groups - Target group focus: Homeless and non-insured people
Vulnerable groups, such as homeless and non-insured people, have a poorer physical and mental health status than comparable populations and usually have no or difficult access to standard health care. Social organisations provide basic health and social care services for these groups of people. Against this background, we searched for evaluation methods for the benefit assessment of easily accessible, outpatient health centers and described the methods, indicators, and instruments used in evaluation studies and reports of comparable services.
Publication: LBI-HTA Project report No. 114: https://eprints.aihta.at/1195/
Contact: Roman Winkler, Inanna Reinsperger
Announcement
C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections
Infection markers such as the C-reactive protein (CRP) can be used in addition to the clinical diagnosis of an infectious disease. So far, CRP tests have been carried out in the laboratory; CRP "point-of-care-testing" (POCT) refers to measurements close to the patient in primary care. The result is available within minutes. CRP POCT is intended to assist the physician to rule out a severe bacterial infection and support a decision on the need for antibiotic prescription.
Publication: LBI-HTA Project report No. 116: https://eprints.aihta.at/1194/
Contact: Sabine Ettinger
Announcement
Horizon Scanning in Oncology - Reports
We are pleased to introduce our two new HSO reports.
DSD HSO No. 86
Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
DSD HSO No. 87
Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC)
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Über Open Innovation in Science zu zwei neuen Ludwig Boltzmann Instituten für Digital Health
- MR-LINAC zur Strahlentherapie in onkologischen Indikationen
- 3D-Druck in der Medizin: Quo vadis?
- Vollständig bioresorbierbare Stents zur Behandlung der koronaren Herzkrankheit
- Natürliche (vaginale) Geburt: Evidenzberichte als Unterstützung für S3-Leitlinie
- Termine
- Themen-Vorschau
Announcement
Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease)
CAD is a disease defined as the manifestation of arteriosclerosis in the coronary arteries and is the leading cause of death in Europe. This systematic review evaluates the current evidence on the efficacy and safety of bioresorbable stents, the latest generation of stents in percutaneous coronary intervention (PCI) in the treatment of CAD, compared to traditional revascularisation strategies (PCI with permanent metal stents or coronary artery bypass graft surgery).
Based on evidence from eight RCTs, the fully bioresorbable everolimus-eluting stent Absorb® BVS is considered to be less effective and to have a worse safety profile compared with everolimus- or biolimus-eluting permanent metal stents. There is insufficient evidence to determine whether Absorb® BVS is considered less effective or less safe than other revascularisation strategies. There is insufficient evidence to determine whether the other four currently CE-certificated fully bioresorbable sent systems [DESolve®, Magmaris (Dreams 2G), Art Pure or Fantom®] are more effective than (or at least as effective as) and/or have better (or at least similar) safety profiles compared with drug-eluting permanent metal stents or other revascularisation strategies.
Publication: Decision Support Document No. 81/1.Update: https://eprints.aihta.at/1191/
Contact: Judit Erdos
Announcement
Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis
Since 2006, natalizumab is used for the treatment of relapsing-remitting multiple sclerosis. Assessing seven studies, which met the inclusion criteria, the present project report investigated the clinical efficacy and safety of natalizumab compared to alternative immunomodulating drugs for a treatment period of at least 36 months.
Publication: LBI-HTA Project report No. 112: https://eprints.aihta.at/1190/
Contact: Eva Fuchs
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Digitalisierung der Gesundheitsversorgung: digitale Transformation
- Transkatheter-Aortenklappenimplantation (TAVI) bei PatientInnen mit mittlerem Operationsrisiko
- Psychologische und pharmakologische Behandlungen für Erwachsene mit Posttraumatischer Belastungsstörung (PTSD)
- Protonentherapie: Evidenz für/ gegen eine Indikationsausweitung
- Extrakorporale Stoßwellentherapie bei orthopädischen Indikationen
- Termine
- Themen-Vorschau
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: GenDiagnostik – Nutzen Pharmakogenetischer Tests
- Arzneimittelerstattung im stationären Sektor in Österreich
- Kardioverter-Defibrillator (LifeVest®) zur Prävention von plötzlichem Herzstillstand
- Inhalationssedierung mit Lachgas (N2O) in der Zahnmedizin
- Screening und Vorsorge für Kinder und Jugendliche von 6-14 Jahren – Länderübersicht und Leitliniensynopse
- Termine
- Themen-Vorschau
